Establishes a commission to study maximum allowable costs lists used by payers and pharmaceutical benefit managers.

The bill establishes a special commission to investigate the use of maximum allowable costs lists, which determine the maximum amount health plans will pay for certain prescription drugs. The commission will review current practices, industry-wide standardization, and transparency in developing and utilizing these lists. The commission will submit its findings and any draft legislation to relevant committees and clerks within 180 days of the act's passage.

Establishes a commission to study maximum allowable costs lists used by payers and pharmaceutical benefit managers.

The bill establishes a special commission to investigate the use of maximum allowable costs lists, which determine the maximum amount health plans will pay for certain prescription drugs. The commission will review current practices, industry-wide standardization, and transparency in developing and utilizing these lists. The commission will submit its findings and any draft legislation to relevant committees and clerks within 180 days of the act's passage.